DK0585705T3 - Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis - Google Patents

Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis

Info

Publication number
DK0585705T3
DK0585705T3 DK93113072T DK93113072T DK0585705T3 DK 0585705 T3 DK0585705 T3 DK 0585705T3 DK 93113072 T DK93113072 T DK 93113072T DK 93113072 T DK93113072 T DK 93113072T DK 0585705 T3 DK0585705 T3 DK 0585705T3
Authority
DK
Denmark
Prior art keywords
bacterial meningitis
monoclonal anti
tnf antibodies
treat bacterial
bacterial
Prior art date
Application number
DK93113072T
Other languages
English (en)
Inventor
Richard F Hector
Michael S Collins
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Application granted granted Critical
Publication of DK0585705T3 publication Critical patent/DK0585705T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DK93113072T 1992-08-28 1993-08-16 Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis DK0585705T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93793992A 1992-08-28 1992-08-28

Publications (1)

Publication Number Publication Date
DK0585705T3 true DK0585705T3 (da) 1999-07-26

Family

ID=25470604

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93113072T DK0585705T3 (da) 1992-08-28 1993-08-16 Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis

Country Status (6)

Country Link
US (1) US5616321A (da)
EP (1) EP0585705B1 (da)
AT (1) ATE172880T1 (da)
DE (1) DE69321909T2 (da)
DK (1) DK0585705T3 (da)
ES (1) ES2121907T3 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
DE69427928T3 (de) † 1993-03-05 2012-05-10 Bayer Healthcare Llc Humane monoklonale anti-TNF alpha Antikörper
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
TWI327597B (en) 2001-08-01 2010-07-21 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
EP2336179A1 (en) 2002-11-08 2011-06-22 Ablynx N.V. Stabilized single domain antibodies
WO2004050683A2 (en) * 2002-12-02 2004-06-17 Abgenix, Inc. Antibodies directed to tumor necrosis factor and uses thereof
US7101978B2 (en) * 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
JP4484664B2 (ja) * 2003-11-27 2010-06-16 キヤノン株式会社 記録ヘッドカートリッジ
US7435799B2 (en) * 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
TWI556829B (zh) 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
EP2500037A3 (en) 2005-05-16 2012-10-24 Abbott Biotechnology Ltd Use of TNF alpha inhibitor for treatment of erosive polyarthritis
CA2962819C (en) 2005-05-18 2021-07-27 Ablynx Nv Improved nanobodies against human serum albumin
RU2466740C2 (ru) 2006-04-05 2012-11-20 Эбботт Байотекнолоджи Лтд. Очистка антитела
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9155784B2 (en) 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2948178A4 (en) 2013-01-25 2016-07-20 Thymon Llc COMPOSITIONS FOR THE SELECTIVE REDUCTION OF CIRCULATING BIOACTIVE SOLUBLE TNF AND METHODS OF TREATING A TNF MEDIATION DISEASE
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
EP2803365A1 (en) 2013-05-14 2014-11-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Use of clonazepam in combination with antibiotic in the treatment of bacterially induced meningitis
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016160976A2 (en) 2015-03-30 2016-10-06 Abbvie Inc. Monovalent tnf binding proteins
EP3078675A1 (en) 2015-04-10 2016-10-12 Ares Trading S.A. Induction dosing regimen for the treatment of tnf alpha mediated disorders
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JOP20190162A1 (ar) 2016-12-30 2019-06-27 Biocad Joint Stock Co تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
DE3631229A1 (de) * 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
JP2647427B2 (ja) * 1987-04-24 1997-08-27 帝人株式会社 被検者の病態の判定のための検出方法、モノクロ−ナル抗体および検出キット
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
JP2638652B2 (ja) * 1988-07-18 1997-08-06 カイロン・コーポレーション カケクチンと反応するモノクロナール抗体
EP0355067A1 (en) * 1988-08-19 1990-02-21 Celltech Limited Pharmaceutical products for anti-neoplastic therapy
US5360716A (en) * 1988-10-24 1994-11-01 Otsuka Pharmaceutical Co., Ltd. Human tumor necrosis factor αspecific monoclonal antibody and method for detecting human tumor necrosis factor α
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
GB8921123D0 (en) * 1989-09-19 1989-11-08 Millar Ann B Treatment of ards
JPH06500323A (ja) * 1990-08-27 1994-01-13 ペプチド　テクノロジィ　リミテッド ウイルス性感染の治療方法
GB9028123D0 (en) * 1990-12-28 1991-02-13 Erba Carlo Spa Monoclonal antibodies against human tumor necrosis factor alpha
ES2156859T5 (es) * 1991-03-18 2008-03-16 New York University Anticuerpos monoclonales y quimericos especificos para el factor de necrosis tumoral humano.
EP0663836B1 (en) * 1992-10-08 1997-07-09 The Kennedy Institute Of Rheumatology Treatment of autoimmune and inflammatory disorders
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
CA2177570A1 (en) * 1993-12-01 1995-06-08 Graham Douglas Fischer Jackson Method of treating intestinal disorders

Also Published As

Publication number Publication date
DE69321909T2 (de) 1999-04-01
EP0585705A1 (en) 1994-03-09
DE69321909D1 (de) 1998-12-10
ATE172880T1 (de) 1998-11-15
US5616321A (en) 1997-04-01
EP0585705B1 (en) 1998-11-04
ES2121907T3 (es) 1998-12-16

Similar Documents

Publication Publication Date Title
DK0585705T3 (da) Anvendelse af monoklone anti-TNF-antistoffer til behandling af bakteriel meningitis
AU4688589A (en) A method for treatment of endotoxic shock in a mammal
GB9115364D0 (en) Antibody
DE69833059D1 (de) Verwendung von Botulinumtoxin zur Behandlung von Harninkontinenz
DE69221501T2 (de) Verfahren zum vermindern von durch medizinische vorrichtungen bedingten infektionen
ATE117434T1 (de) Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
DK0744957T3 (da) Præparat og fremgangsmåde til forebyggelse og behandling af inflammation med immunoglobulin A
DK149990A (da) Familie af modificerede antistoffer med hoej affinitet til cancerbehandling
DE68921979T2 (de) Antikörper für die antilymphozyten-antikörpertherapie.
DK0792162T3 (da) Anvendelse af antistoffer til blokering af virkningerne af grampositive bakterier og mycobakterier
NO934655L (no) Legemiddel for gram-positive sykdommer i akvatiske arter
ATE143267T1 (de) Methode zur behandlung oder verhütung von fettleibigkeit
DE3773059D1 (de) Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
DE69527868D1 (de) Monoklonaler Antikörper gegen den tumorzytotoxischen Faktor II (TCF-II)
NO973659L (no) Anvendelse av LCK SH2-spesifikke forbindelser til behandling av autoimmune sykdommer og transplantatavvisning
DE59008759D1 (de) Verwendung von interleukin-2 zur behandlung der endotoxinämie.
DE69001240T2 (de) Methoden zur verwendung von 2-isopropyl-2-phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
EA200101271A1 (ru) Блокирующее моноклональное антитело к vla-1 и его применение для лечения воспалительных заболеваний
DE68924963D1 (de) Zusammensetzungen und Methoden zur Behandlung und Vorbeugung von Gram-Negativen-Infektionen.
TR199700791T1 (xx) Kendiliğinden bağışıklığı olan hastalıkların ve allograft rejeksiyonun tedavisi için LCK SH2 spesifik bileşimlerinin kullanılması.